Abstract
Single autosomal trisomy is a common numerical cytogenetic abnormality in hematological malignancies, and shows a predilection for myeloid disorders. While the strong morphologic correlation as for chromosomal translocations is lacking, phenotypic associations are observed for the trisomies. Trisomy 10 is associated with aberrant CD7 expression in acute myeloid leukemia (AML), and trisomy 13 is associated with immature subtypes of AML having hand-mirror blast morphology. Cytogenetic abnormalities have been shown to be the most valuable prognostic determinant in AML and myelodysplastic syndrome (MDS). Trisomy 8, the commonest of the trisomies in myeloid disorders, is associated with an intermediate prognosis, while poor clinical outcome has been described in AML with trisomy 11 and trisomy 13. Additionally, the presence of a trisomy allows the application of fluorescence in situ hybridization (FISH) techniques in monitoring therapy response, detection of minimal residual disease and determination of l ineage involvement. The role of trisomy in pathogenesis remains to be defined and a gene dosage effect has been suspected. The recent finding of MLL gene duplication in association with trisomy 11 represents the first documented gene rearrangement in this setting. Finally, whether single autosomal trisomy is a primary or secondary cytogenetic abnormality is presently unclear. Evidence in favor of a secondary change includes frequent association with well-defined structural changes and translocations, and appearance of trisomy with disease evolution. In this respect, it is interesting to note that trisomy may be a cytogenetic marker for an underlying cryptic gene rearrangement, for example trisomy 22 and CBFbeeta MYH11 fusion in AML. This review will summarize the current understanding of single autosomal trisomy in myeloid disorders.
Keywords: Single Autosomal Trisomy, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Aberrant CD7 expression, Myeloid Leukemia AML, Fluorescence in situ hybridization, MLL Gene Duplication, Myeloid Disorders, Trisomy, Leukemogenesis
Current Genomics
Title: Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Volume: 1 Issue: 2
Author(s): S. K. Ma and T. S.K. Wan
Affiliation:
Keywords: Single Autosomal Trisomy, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Aberrant CD7 expression, Myeloid Leukemia AML, Fluorescence in situ hybridization, MLL Gene Duplication, Myeloid Disorders, Trisomy, Leukemogenesis
Abstract: Single autosomal trisomy is a common numerical cytogenetic abnormality in hematological malignancies, and shows a predilection for myeloid disorders. While the strong morphologic correlation as for chromosomal translocations is lacking, phenotypic associations are observed for the trisomies. Trisomy 10 is associated with aberrant CD7 expression in acute myeloid leukemia (AML), and trisomy 13 is associated with immature subtypes of AML having hand-mirror blast morphology. Cytogenetic abnormalities have been shown to be the most valuable prognostic determinant in AML and myelodysplastic syndrome (MDS). Trisomy 8, the commonest of the trisomies in myeloid disorders, is associated with an intermediate prognosis, while poor clinical outcome has been described in AML with trisomy 11 and trisomy 13. Additionally, the presence of a trisomy allows the application of fluorescence in situ hybridization (FISH) techniques in monitoring therapy response, detection of minimal residual disease and determination of l ineage involvement. The role of trisomy in pathogenesis remains to be defined and a gene dosage effect has been suspected. The recent finding of MLL gene duplication in association with trisomy 11 represents the first documented gene rearrangement in this setting. Finally, whether single autosomal trisomy is a primary or secondary cytogenetic abnormality is presently unclear. Evidence in favor of a secondary change includes frequent association with well-defined structural changes and translocations, and appearance of trisomy with disease evolution. In this respect, it is interesting to note that trisomy may be a cytogenetic marker for an underlying cryptic gene rearrangement, for example trisomy 22 and CBFbeeta MYH11 fusion in AML. This review will summarize the current understanding of single autosomal trisomy in myeloid disorders.
Export Options
About this article
Cite this article as:
Ma K. S. and Wan S.K. T., Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome, Current Genomics 2000; 1 (2) . https://dx.doi.org/10.2174/1389202003351553
DOI https://dx.doi.org/10.2174/1389202003351553 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism The Role of FLT3 Kinase as an AML Therapy Target
Current Pharmaceutical Design Kit: Molecule of Interest for the Diagnosis and Treatment of Mastocytosis and other Neoplastic Disorders
Current Cancer Drug Targets Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS
Infectious Disorders - Drug Targets Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Building a Long Distance Training Program to Enhance Clinical Cancer Research Capacity in Puerto Rico
Reviews on Recent Clinical Trials Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Antitumor Effect of Pomolic Acid in Acute Myeloid Leukemia Cells Involves Cell Death, Decreased Cell Growth and Topoisomerases Inhibition
Anti-Cancer Agents in Medicinal Chemistry NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition